Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Item No. 37442

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Tat-βsyn-degron is an α-synuclein knockdown peptide.1 It is composed of the HIV-1 Tat plasma membrane transduction domain, the α-synuclein binding domain βsyn which corresponds to amino acids 36-45 of β-synuclein, and the proteasomal targeting domain degron. Tat-βsyn-degron binds to recombinant α-synuclein in a peptide-protein binding assay and reduces α-synuclein levels in primary rat cortical neuron cultures, an effect that can be prevented by the proteasomal inhibitor MG132. In vivo, Tat-βsyn-degron (40 mg/kg) reduces brain α-synuclein levels in M38 transgenic mice that overexpress human A53T mutant α-synuclein. It also reduces phosphorylated α-synuclein levels in the substantia nigra and the pons, as well as neuroinflammation in a mouse model of spreading synucleinopathy induced by α-synuclein preformed fibrils. Tat-βsyn-degron (6 µmol/kg, i.p.) protects against dopaminergic neuron loss and rescues motor deficits in a mouse model of MPTP-induced Parkinson’s disease.
WARNING This product is not for human or veterinary use.
1. Development of an α-